Vivek Sukumar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Vivek Sukumar has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Avanish Saklani
Division of Colo‐Rectal and Peritoneal Surface Oncology, Department of Surgical Oncology Tata Memorial Hospital, Homi Bhabha National Institute Mumbai India
20 shared publications - Mufaddal Kazi
Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, India
15 shared publications Ashwin Desouza
Division of Colorectal Oncology, Department of Surgical Oncology Tata Memorial Hospital Mumbai India
10 shared publications- Sanket Bankar
Tata Memorial Hospital Mumbai India
7 shared publications - Swapnil Patel
Department of Surgical Oncology, Upkar Hospital and Cancer Institute, Varanasi, India
7 shared publications - Diwakar Pandey
Division of Colorectal Oncology Department of Surgical Oncology Tata Memorial Centre Homi Bhabha National Institue Mumbai India
4 shared publications
Latest Publications
- Open Access
MIS-CYTO: A prospective, multi-center, observational study for validation of oncological adequacy of minimally invasive cytoreductive surgery for peritoneal malignancies with limited peritoneal spread at systematic mini-laparotomy by INDEPSO
Background: The role of minimally-invasive cytoreductive surgery (MI-CRS) in low volume peritoneal disease has been explored but lacks robust evidence demonstrating oncological adequacy and non-inferiority to open CRS. The major challenges of MI-CRS are its technical complexity and chances of missing disease which could have detrimental oncological outcomes. The only means of resolving the dilemma of missed disease is to convert the procedure to open surgery and confirming the findings of MI approach. The “Minimally InvaSive CYTOreductive surgery” (MIS-CYTO) study is a prospective observational study that will evaluate the oncological adequacy of MI-CRS at systematic mini-laparotomy in patients with low volume peritoneal disease. Methods: This single-arm study which will include 100 patients with primary and secondary peritoneal malignancies with a peritoneal cancer index (PCI)< 10 treated by MI-CRS. Patients will be recruited over 3 years and followed up for 5 years. All patients will undergo a staging laparoscopy (SL) with video documentation according to the study format. Patients who undergo subsequent MI-CRS will be included in the per-protocol population. At the end of MI-CRS video documentation of the resection sites is performed followed by a systematic mini-laparotomy for exploration of the abdominal cavity for any residual disease. The presence of residual disease will be confirmed on pathological evaluation. The primary end point is the incidence of missed disease during MI-CRS that is detected during mini-laparotomy. Quality assessment of SL and MI-CRS will be performed by an independent two-member committee. Patients undergoing conversion to open cytoreductive surgery will comprise the comparator group for studying the secondary end-point which include the sites of missed disease, perioperative outcomes and survival outcomes. Survival endpoints will be measured from the date of surgery to the event: overall survival (OS) will be defined by death due to any cause, and progression-free or relapse-free survival (PFS/RFS) by any recurrence or death whichever comes first. Ethics and Registration: The study protocol is approved by the ethics committee of Shalby Cancer and Research Institute on 7 th October 2024 (EC/069/02). The study is registered under the Clinical Trials Registry of India; subsidiary of clinicaltrials.gov (CTRI/2024/11/076312). Strengths and limitations: The study will be the first to demonstrate the oncological adequacy or inadequacy of the MI-CRS The methodology and surgical protocol are robust and should minimize heterogeneity in surgical practices in the study If the oncological inadequacy of MI-CRS is not demonstrated, its use should be limited in patients with limited peritoneal disease. Two independent experts will review the adequacy of staging laparoscopy and MI-CRS both The stringent methodology could be a deterrent for surgeons/ centres to participate in the study, specifically performing a systematic mini-laparotomy for those surgeons who prefer to deliver specimens through a natural orifice.
Open AccessMIS-CYTO: A prospective, multi-center, observational study for validation of oncological adequacy of minimally invasive cytoreductive surgery for peritoneal malignancies with limited peritoneal spread at systematic mini-laparotomy by INDEPSO
Background: The role of minimally-invasive cytoreductive surgery (MI-CRS) in low volume peritoneal disease has been explored but lacks robust evidence demonstrating oncological adequacy and non-inferiority to open CRS. The major challenges of MI-CRS are its technical complexity and chances of missing disease which could have detrimental oncological outcomes. The only means of resolving the dilemma of missed disease is to convert the procedure to open surgery and confirming the findings of MI approach. The “Minimally InvaSive CYTOreductive surgery” (MIS-CYTO) study is a prospective observational study that will evaluate the oncological adequacy of MI-CRS at systematic mini-laparotomy in patients with low volume peritoneal disease. Methods: This single-arm study which will include 100 patients with primary and secondary peritoneal malignancies with a peritoneal cancer index (PCI)< 10 treated by MI-CRS. Patients will be recruited over 3 years and followed up for 5 years. All patients will undergo a staging laparoscopy (SL) with video documentation according to the study format. Patients who undergo subsequent MI-CRS will be included in the per-protocol population. At the end of MI-CRS video documentation of the resection sites is performed followed by a systematic mini-laparotomy for exploration of the abdominal cavity for any residual disease. The presence of residual disease will be confirmed on pathological evaluation. The primary end point is the incidence of missed disease during MI-CRS that is detected during mini-laparotomy. Quality assessment of SL and MI-CRS will be performed by an independent two-member committee. Patients undergoing conversion to open cytoreductive surgery will comprise the comparator group for studying the secondary end-point which include the sites of missed disease, perioperative outcomes and survival outcomes. Survival endpoints will be measured from the date of surgery to the event: overall survival (OS) will be defined by death due to any cause, and progression-free or relapse-free survival (PFS/RFS) by any recurrence or death whichever comes first. Ethics and Registration: The study protocol is approved by the ethics committee of Shalby Cancer and Research Institute on 7 th October 2024 (EC/069/02). The study is registered under the Clinical Trials Registry of India; subsidiary of clinicaltrials.gov (CTRI/2024/11/076312). Strengths and limitations: The study will be the first to demonstrate the oncological adequacy or inadequacy of the MI-CRS The methodology and surgical protocol are robust and should minimize heterogeneity in surgical practices in the study If the oncological inadequacy of MI-CRS is not demonstrated, its use should be limited in patients with limited peritoneal disease. Two independent experts will review the adequacy of staging laparoscopy and MI-CRS both The stringent methodology could be a deterrent for surgeons/ centres to participate in the study, specifically performing a systematic mini-laparotomy for those surgeons who prefer to deliver specimens through a natural orifice.
- 1 December 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 10 (10) , e2400306
INDEPSO-ISPSM Consensus on Peritoneal Malignancies: Management of Colorectal Peritoneal Metastases
PURPOSE: This manuscript reports the results of the Indian Network for Development of Peritoneal Surface Oncology and Indian Society of Peritoneal Surface Malignancies (INDEPSO-ISPSM) consensus that aimed to provide recommendations for some important aspects management of patients with colorectal peritoneal metastases (CPM) and address some issues unique to India. METHODS: The modified Delphi technique was used with two rounds of voting. There were 29 questions on nine main topics—the role of cytoreductive surgery (CRS), patient selection for CRS, preoperative workup, role of systemic chemotherapy (SC), CPM with other visceral metastases, molecular profile, hyperthermic intraperitoneal chemotherapy (HIPEC) and other modalities of intraperitoneal chemotherapy (IPC), prophylactic/preventive strategies, and surveillances after CRS. A consensus was achieved if anyone option received >70 votes (strong consensus >90%). RESULTS: Forty-eight surgical (n = 41) and gastrointestinal (n = 7) oncologists were invited; 44 agreed to participate. The response rate was 95.4% (42/44) in round 1 and 93.1% (41/44) in round 2. Overall, a consensus was achieved on 23/29 (79.3%) questions (strong consensus on 6/29 [20.6%]). The panel strongly recommended considering surgery for limited CPM with limited liver metastases (92.5%), not altering the surgical approach in patients with KRAS mutations (91.67%), and limiting the use of IPC for unresectable CPM outside clinical trials (95%). Adjuvant SC was recommended for all patients undergoing CRS (89.47%). CRS is a therapeutic option for selected patients with CPM including those with metachronous CPM (79.49) and signet ring cell cancers (76.92%). HIPEC was recommended outside clinical trials only for patients with peritoneal cancer index 11-15(80%). CONCLUSION: The panel recommended CRS for most indications but was very selective in recommending HIPEC and IPC outside clinical trials. These recommendations should be a useful resource in clinical decision making for clinicians treating CPM in India and regions with a similar sociodemographic background.
- 1 December 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 10 (10) , e2400306
INDEPSO-ISPSM Consensus on Peritoneal Malignancies: Management of Colorectal Peritoneal Metastases
PURPOSE: This manuscript reports the results of the Indian Network for Development of Peritoneal Surface Oncology and Indian Society of Peritoneal Surface Malignancies (INDEPSO-ISPSM) consensus that aimed to provide recommendations for some important aspects management of patients with colorectal peritoneal metastases (CPM) and address some issues unique to India. METHODS: The modified Delphi technique was used with two rounds of voting. There were 29 questions on nine main topics—the role of cytoreductive surgery (CRS), patient selection for CRS, preoperative workup, role of systemic chemotherapy (SC), CPM with other visceral metastases, molecular profile, hyperthermic intraperitoneal chemotherapy (HIPEC) and other modalities of intraperitoneal chemotherapy (IPC), prophylactic/preventive strategies, and surveillances after CRS. A consensus was achieved if anyone option received >70 votes (strong consensus >90%). RESULTS: Forty-eight surgical (n = 41) and gastrointestinal (n = 7) oncologists were invited; 44 agreed to participate. The response rate was 95.4% (42/44) in round 1 and 93.1% (41/44) in round 2. Overall, a consensus was achieved on 23/29 (79.3%) questions (strong consensus on 6/29 [20.6%]). The panel strongly recommended considering surgery for limited CPM with limited liver metastases (92.5%), not altering the surgical approach in patients with KRAS mutations (91.67%), and limiting the use of IPC for unresectable CPM outside clinical trials (95%). Adjuvant SC was recommended for all patients undergoing CRS (89.47%). CRS is a therapeutic option for selected patients with CPM including those with metachronous CPM (79.49) and signet ring cell cancers (76.92%). HIPEC was recommended outside clinical trials only for patients with peritoneal cancer index 11-15(80%). CONCLUSION: The panel recommended CRS for most indications but was very selective in recommending HIPEC and IPC outside clinical trials. These recommendations should be a useful resource in clinical decision making for clinicians treating CPM in India and regions with a similar sociodemographic background.
- 2 March 2023
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 49 (7) , 1307-1313
Factors predicting successful resolution and long-term outcomes of benign anastomotic strictures following rectal cancer surgery
- 2 March 2023
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 49 (7) , 1307-1313
Factors predicting successful resolution and long-term outcomes of benign anastomotic strictures following rectal cancer surgery
- 3 November 2022
- Published by Wiley in Colorectal Disease
- Vol. 25 (4) , 813-814
Laparoscopic low anterior resection in a case of locally advanced rectal cancer after neoadjuvant short course radiation: A surgical perspective – A video vignette
- 3 November 2022
- Published by Wiley in Colorectal Disease
- Vol. 25 (4) , 813-814
Laparoscopic low anterior resection in a case of locally advanced rectal cancer after neoadjuvant short course radiation: A surgical perspective – A video vignette
- 12 September 2022
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 65 (12) , e1072
Laparoscopic Anterior Resection With Supratrigonal Cystectomy in a Case of Locally Advanced Sigmoid Cancer
- 12 September 2022
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 65 (12) , e1072
Laparoscopic Anterior Resection With Supratrigonal Cystectomy in a Case of Locally Advanced Sigmoid Cancer
- 16 August 2022
- Published by Wiley in Colorectal Disease
- Vol. 25 (1) , 165-166
Avoiding conversion in laparoscopic resections for locally advanced rectal cancers: A video vignette
- 16 August 2022
- Published by Wiley in Colorectal Disease
- Vol. 25 (1) , 165-166
Avoiding conversion in laparoscopic resections for locally advanced rectal cancers: A video vignette
- 25 July 2022
- Published by Wiley in Colorectal Disease
- Vol. 24 (12) , 1516-1525
Learning curves for minimally invasive total mesorectal excision beyond the competency phase – a risk‐adjusted cumulative sum analysis of 1000 rectal resections
Aim: The learning curve of total mesorectal excision (TME) by minimally invasive surgery (MIS) beyond the competency phase has not been adequately reported with large numbers or using a statistical control limit. The aim of this work was to study the learning curve of MIS TME in the proficiency phase.Method: Risk‐adjusted (RA) cumulative sum (CUSUM) and RA Bernoulli CUSUM charts were plotted for sequential MIS TME performed by a surgical team over 1000 cases. Surgical failure, a composite endpoint of conversions, complications of grade IIIA or above, R1 resections and inadequate nodal yield were used to monitor the performance.Results: The RA CUSUM detected an inflection point around the 600th operation. Two peaks were identified that could be traced back to probable causes of surgical failure. Similar inflection points were detected at the 450th case for laparoscopic TME and the 367th case for sphincter preservation. No single definite threshold point was noticed for robotic or abdominoperineal operations. At no point did the curves cross the safety threshold. The probability of surgical failure reduced with increasing experience in the multivariate regression (OR 0.899, p = 0.000). This association persisted irrespective of the surgical approach (laparoscopic versus robotic) or the type of operation (sphincter preservation versus abdominoperineal resection).Conclusion: The learning curves for MIS TME did not cross the safety threshold beyond the competency phase. However, a 10% reduction of relative risk in surgical failure was observed for every 100 cases operated on.
- 25 July 2022
- Published by Wiley in Colorectal Disease
- Vol. 24 (12) , 1516-1525
Learning curves for minimally invasive total mesorectal excision beyond the competency phase – a risk‐adjusted cumulative sum analysis of 1000 rectal resections
Aim: The learning curve of total mesorectal excision (TME) by minimally invasive surgery (MIS) beyond the competency phase has not been adequately reported with large numbers or using a statistical control limit. The aim of this work was to study the learning curve of MIS TME in the proficiency phase.Method: Risk‐adjusted (RA) cumulative sum (CUSUM) and RA Bernoulli CUSUM charts were plotted for sequential MIS TME performed by a surgical team over 1000 cases. Surgical failure, a composite endpoint of conversions, complications of grade IIIA or above, R1 resections and inadequate nodal yield were used to monitor the performance.Results: The RA CUSUM detected an inflection point around the 600th operation. Two peaks were identified that could be traced back to probable causes of surgical failure. Similar inflection points were detected at the 450th case for laparoscopic TME and the 367th case for sphincter preservation. No single definite threshold point was noticed for robotic or abdominoperineal operations. At no point did the curves cross the safety threshold. The probability of surgical failure reduced with increasing experience in the multivariate regression (OR 0.899, p = 0.000). This association persisted irrespective of the surgical approach (laparoscopic versus robotic) or the type of operation (sphincter preservation versus abdominoperineal resection).Conclusion: The learning curves for MIS TME did not cross the safety threshold beyond the competency phase. However, a 10% reduction of relative risk in surgical failure was observed for every 100 cases operated on.
- 27 June 2022
- Published by Wiley in Colorectal Disease
- Vol. 24 (12) , 1622-1623
Laparoscopic extended inter‐sphincteric resection for low rectal cancer involving the levator‐ani muscle complex: A video vignette
- 27 June 2022
- Published by Wiley in Colorectal Disease
- Vol. 24 (12) , 1622-1623
Laparoscopic extended inter‐sphincteric resection for low rectal cancer involving the levator‐ani muscle complex: A video vignette
- 1 May 2022
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 48 (5) , 1110-1116
Learning curve analysis for lateral pelvic lymph node dissection in rectal cancers – Outcomes improve with experience
- 1 May 2022
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 48 (5) , 1110-1116
Learning curve analysis for lateral pelvic lymph node dissection in rectal cancers – Outcomes improve with experience
- 18 January 2022
- Published by Wiley in Colorectal Disease
- Vol. 24 (5) , 672
Robotic‐assisted abdominoperineal resection with extended total mesorectal excision – A video vignette
- 18 January 2022
- Published by Wiley in Colorectal Disease
- Vol. 24 (5) , 672
Robotic‐assisted abdominoperineal resection with extended total mesorectal excision – A video vignette